Quarterly report pursuant to Section 13 or 15(d)

Revenue - Potential Milestone Payments (Details)

v3.21.1
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements
$ in Millions
Mar. 31, 2021
USD ($)
Research, Development, Regulatory & Commercial Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 2,086
Research, Development, Regulatory & Commercial Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 1,096
Research, Development, Regulatory & Commercial Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 236
Research, Development, Regulatory & Commercial Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 754
Sales Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 4,936
Sales Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 4,275
Sales Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 211
Sales Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 450